Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) View the PDF document
Table of Contents
Open this folder and view contentsOpening Ceremony
Open this folder and view contentsGood regulatory practice
Open this folder and view contentsGood certification practice
Open this folder and view contentsCounterfeit drugs: challenges and solutions
Close this folderCurrent issues in regulation and quality
View the documentEnforcement of regulatory functions
View the documentQuality of starting materials and the role of pharmacopoeias
View the documentImplementation of good manufacturing practices
View the documentUpgrade of local production
View the documentRecommendations
Open this folder and view contentsInternational Conference on Harmonization: implementation and implications
Open this folder and view contentsDrug utilization studies
Open this folder and view contentsInternational Conference on Harmonization and the common technical document
Open this folder and view contentsKeynote address
Open this folder and view contentsGlobal and national efforts to reduce tobacco use
Open this folder and view contentsElectronic communication in the regulatory process
Open this folder and view contentsTransparency in monitoring the safety of medicines
Open this folder and view contentsPharmaceutical products for use in special groups
Open this folder and view contentsNeed for Bioequivalence
Open this folder and view contentsAntimicrobial resistance: battling the bugs
Open this folder and view contentsSafety issues of plasma-derived medicinal products
Open this folder and view contentsHerbal medicines
Open this folder and view contentsRegulation and access to essential drugs
View the documentParticipants
View the documentBack cover
 

Current issues in regulation and quality

Moderators: Mr J. Reynier, France, and Ms M. Tala fallow, The Gambia

Drug regulation is an essential public health function to combat the current global and local challenges concerning poor quality and circulation of ineffective and harmful drugs. Worldwide, only one out of six countries has established fully-developed drug regulatory capacity. Moreover, two out of six countries have very limited drug regulation in place.

Harmonization efforts are essential to promote safe trade in starting materials, intermediates, and finished products, thereby assuring that safe products reach patients.

WHO strategies to meet these challenges include efforts to:


• provide global guidance in the areas of quality, safety and efficacy, drug information, and harmonization.

• strengthen national drug regulation through information exchange and networking, provision of guidelines, manuals and training programmes, and direct support to countries.

 

to previous section to next section
 

Last updated: April 24, 2012